Dimensional US Vector Equity ETF provides value with earnings growth. Read why DXUV's higher volatility and quality concerns ...

Visit our YouTube page (opens in a new tab) Visit our Facebook page (opens in a new tab) Visit our Instagram page (opens in a new tab) Visit our X page (opens in a new tab) Visit our RSS Feed page ...

Geoff Bennett: That department has been a target of critics for nearly as long as it's existed, but President Trump and other Republicans want to go all the way this time, calling the department ...

Recent Company Highlights Clinical Hold Lifted for Cadisegliatin Program. In March 2025, vTv Therapeutics announced that the clinical hold placed by the FDA in July 2024 on the cadisegliatin ...

Any type of violence is bad for the society, Rashtriya Swayamsewak Sangh (RSS) national publicity in-charge Sunil Ambekar said on Wednesday (March 19, 2025). On being asked if RSS thinks that ...

CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ...

In a telephone call with Venezuelan channel VTV, the Minister of Interior, Justice and Peace, Diosdado Cabello, said none of them were linked to Tren de Aragua. Following this, two more flights ...

vTv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial as an oral treatment of type 1 diabetes. Stock of the company is up ...

FDA lifts hold on vTv's Phase 3 trial for cadisegliatin in type 1 diabetes, allowing the company to proceed with a shortened six-month study vTv plans to amend the trial protocol, reducing its ...

Shares of vTv Therapeutics (NASDAQ:VTVT) jumped 27.87% to $18.95 as of 9:53 AM ET after the company announced that the U.S. FDA has lifted the clinical hold on its late-stage trial for ...